Several brokerages have updated their recommendations and price targets on shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) in the last few weeks:7/29/2026 – Madrigal Pharmaceuticals was given a new $587.00 price target by Canaccord Genuity Group Inc..7/27/2026 – Madrigal Pharmaceuticals is now covered by Wells Fargo & Company. 7/17/2026 – Madrigal Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings. 7/17/2026 – Madrigal Pharmaceuticals had its “outperform” rating reaffirmed by Citigroup Inc..6/24/2026 – Madrigal Pharmaceuticals had its “overweight” rating reaffirmed by Piper Sandler. 6/11/2026 – Madrigal Pharmaceuticals had its price target lowered by Bank of America Corporation from $550.00 to $542.00. See AlsoReceive News & Ratings for Madrigal Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.